Trending...
- Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again
- 3ptechies Partners with Coolmuster to Give Away Data Recovery Software Licenses
- INAD Warriors' 4th Annual "Dancing with the INAD Stars" Gala
WEST CHESTER, Pa.--(BUSINESS WIRE)--Beth Altman, former managing partner at accounting firm KPMG LLP San Diego, has joined Papyrus Therapeutics Inc. as an independent director of the Company's Board of Directors and as Chair of the Audit Committee.
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
Beth has more than 27 years of experience in accounting, finance, management, business development, strategic planning and corporate governance. During her 25-year career at KPMG LLP, Altman led a team of more than 260 professionals to provide assurance, tax and advisory services to public and private companies spanning all industry sectors. She also served as the lead audit partner for numerous public and private companies, predominantly in the life sciences and technology sectors. Since her retirement from KPMG LLP in October 2019, she has served on the Board and the Audit Committee of Allscripts Healthcare Inc., and Alphatec Holdings, Inc. and she has served on the Board and as Chair of the Audit Committee of CV Sciences, Inc.
She previously served as a board member of the Corporate Directors Forum, a 501 (c)(6) nonprofit organization focused on helping directors build more effective boards and held a leadership position in the Women Corporate Directors, San Diego Chapter, the world's largest membership organization and community of today's preeminent women leaders in business.
More on The PennZone
- Redefining Proactive Care: The Rise of the Hybrid Concierge Medical Model
- As Canada and America Turn on Each Other, These Two Authors Stay On Speaking Terms
- Benny Turner Revisits Freddie King's Legacy for 50th Anniversary of His Passing
- GitKraken Names Jim Shaw CEO as Software Teams Move From AI Adoption to Multi-Agent Orchestration
- Brévant Guide Launches New National Restaurant Guide Across Canada
CEO Dr Paul Blake stated, "I am delighted that Beth is joining Papyrus Therapeutics. She has a deep experience of business, accounting, and finance, which coupled with her experience on the boards of other life science companies, will be of indispensable value to us as we expand our activities."
About Papyrus Therapeutics Inc.: Papyrus Therapeutics, Inc. (West Chester, PA, USA) is an emerging biopharma company developing novel tumor suppressor-based therapies. Papyrus´ lead therapeutic is a modified, recombinant version of Opioid Binding Protein/Cell Adhesion Molecule-like (OPCML). OPCML is a broadly acting tumor suppressor that is epigenetically silenced in many cancers, leading to tumor invasion and metastasis through deregulation of apoptosis, epithelial-to-mesenchymal transition (EMT) and cellular migration. Classic receptor tyrosine kinase [RTK] inhibition using small molecules has proven highly effective in many cancers, but treatment resistance remains a significant challenge. Delivery of OPCML, which works at the cell surface, can overcome this challenge by reconstituting normal RTK signaling in the tumor.
Contacts
Media
Dr Paul Blake
908 330 6997
pblake@pytxi.com
0 Comments
Latest on The PennZone
- 54 Million Contract. New Chapter as AI Cybersecurity Platform Expands, Margins Surge & Management Signals Confidence. Cycurion, Inc: (NAS DAQ: CYCU)
- MommyAndMe.club Expands Parent-Child Class Directory to All 50 States and Washington, D.C
- Work 365 Deepens TD SYNNEX Integration with Automated Azure Billing
- Award-Winning Author's New Timely Book "Philly Girl" Highlights Centuries of Brave & Bold Women from Philadelphia
- RAS AP Consulting Signals Growth of Managed AP Governance With Digital Expansion, Pipeline Activation, and Trademark Filing Ahead of Esker All Access
- National Nonprofit Lights 200 Landmarks Pink and Blue for Pregnancy and Infant Loss Awareness Month
- Vegan Kingz Unveils Upgraded Digital Platform to Streamline Commercial Foodservice & Wholesale Ordering
- Steve Thompson Launches StickyHealth to Tackle the Retention Gap in the Growing GLP 1 Market
- Qscription Technologies Appoints Dr. Kimberly Beavers as Founding Clinical Advisor
- When Hope Feels Gone, Death2life Is Still Here!
- Sebastian Stroeller Publishes "The MAP Language Canon" — The Complete Practitioner's Guide to Structural Conversation
- OneVizion Appoints Zebra Technologies CIO Matt Ausman to Board of Directors
- GLADYS Magazine Celebrates their 18 Year Anniversary!
- New Townhome Building Released at Heritage at South Brunswick, Offering Private Perimeter Setting and Water Views
- Comics Veteran on Return of Teenage Mutant Ninja Turtles Characters, 3-D Projects, Collaboration with Original 'Star Wars' Toy Engineer
- Flexible Plan Investments Announces Retirement of Executive Vice President Renée Toth
- Sensory Education launches new neuro-affirming psychoeducation book, Sensory Diversity
- Break the Resume Mold: Career Valet Changes How Executives Hunt for Jobs
- Expansive New Worlds Await Peter Darrach Unveils 'The Cleopard and Other Tales from the Second Skin
- James Dooley Named King of AEO at Ceremony in Leigh, England